Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-209 plus fulvestrant versus placebo plus fulvestrant in HR-positive, HER2-negative advanced or metastatic breast cancer after endocrine progression
CTR20220426Phase 3Active
- Sponsor
- BeBetter Med
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bebt-209, fulvestrant in breast cancer, sponsored by BeBetter Med. Started Jun 2022; status: active.
02
Drugs
bebt-209fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20220426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220426.